Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Panbela Therapeutics, Inc. | ex_176448.htm |
| EX-32.1 - EXHIBIT 32.1 - Panbela Therapeutics, Inc. | ex_176447.htm |
| EX-31.2 - EXHIBIT 31.2 - Panbela Therapeutics, Inc. | ex_176446.htm |
| EX-31.1 - EXHIBIT 31.1 - Panbela Therapeutics, Inc. | ex_176445.htm |
| EX-24.1 - EXHIBIT 24.1 - Panbela Therapeutics, Inc. | ex_177167.htm |
| EX-10.25 - EXHIBIT 10.25 - Panbela Therapeutics, Inc. | ex_177933.htm |
| EX-10.22 - EXHIBIT 10.22 - Panbela Therapeutics, Inc. | ex_177932.htm |
| EX-10.10 - EXHIBIT 10.10 - Panbela Therapeutics, Inc. | ex_177931.htm |
| EX-4.1 - EXHIBIT 4.1 - Panbela Therapeutics, Inc. | ex_177165.htm |
| 10-K - FORM 10-K - Panbela Therapeutics, Inc. | snbp20191231_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-213610) of our report dated March 24, 2020 included in this Annual Report on Form 10-K of Sun Biopharma, Inc. (the “Company”), relating to the consolidated financial statements of the Company for the year ended December 31, 2019.
/s/ Cherry Bekaert LLP
Tampa, Florida
March 24, 2020